Geoffrey is the Chief Innovation Officer for Indigo, as well as a Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in nutrition, environmental sustainability, and medicine. He is a co-founder of Indigo, Seres Therapeutics, Axcella Health, Kaleido Biosciences, and others.
Geoffrey served as Chief Technology Officer at Seres Therapeutics, where he led the build-out of the Microbiome Therapeutics platform and the discovery of SER-109, the first clinically-validated Microbiome Therapeutic. He was also VP of Product Discovery at Axcella, where he led the discovery of two clinically-validated drug candidates.
Geoffrey has been named as an inventor on over 100 patents and applications and received more than 20 awards for invention, including the Lemelson-MIT student prize, given to the most innovative student at MIT. He was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.
“I’m motivated by big challenges. Thousands of years ago, agriculture likely enabled human civilization. Today, we need to re-invent it so that it’s better for our health, our climate, and the environment around us—and this needs to be done in a way that scales to meet the needs of the whole world. That’s what our science at Indigo is about.”
